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Objective: To assess effectiveness and tolerability of first- line and conversion to la-
cosamide monotherapy for focal seizures.
Materials and Methods: Retrospective, non- interventional chart review of lacosa-
mide	monotherapy	patients	aged	≥16	years	in	Europe.	Outcomes	included	retention	
rate at observational point (OP) 3 (12 ± 3 months), seizure freedom rates at OP2 
(6 ± 3 months) and OP3 and adverse drug reactions (ADRs).
Results: A total of 439 patients were included (98 first- line and 341 conversion to 
monotherapy;	128	aged	≥65	years	 [25	 first-	line	 and	103	conversion	 to	monother-
apy]). First- line and conversion to monotherapy retention rates were 60.2% (59/98; 
95%	confidence	 interval	 [CI]	49.8%-	70.0%)	and	62.5%	 (213/341;	57.1%-	67.6%),	 re-
spectively. Kaplan- Meier estimates of 12- month retention rates were 81.2% and 
91.4% for first- line and conversion to monotherapy, respectively. First- line and con-
version	 to	 monotherapy	 retention	 rates	 in	 patients	 aged	 ≥65	years	 were	 60.0%	
(38.7%- 78.9%) and 68.9% (59.1%- 77.7%), respectively. At OP2, 66.3% of first- line and 
63.0% of conversion to monotherapy patients were seizure free. At OP3, 60.2% of 
first- line and 52.5% of conversion to monotherapy patients were seizure free. In the 
≥65	years	subgroup,	seizure	freedom	rates	at	OP2	were	72.0%	and	68.0%	for	first-	
line and converted to monotherapy, respectively, and at OP3, 68.0% and 56.3%, re-
spectively.	Overall,	52	of	439	(11.8%)	patients	reported	ADRs	(16.4%	in	≥65	years	
subgroup), most commonly dizziness (5.0%), headache (2.1%) and somnolence (1.6%).
Conclusions: Lacosamide was effective and well tolerated as first- line or conversion 
to monotherapy in a clinical setting in adult and elderly patients with focal seizures.
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1  | INTRODUC TION
The aim of epilepsy treatment is to achieve seizure freedom with-
out clinically significant adverse effects.1 The majority of patients 
with epilepsy attain seizure freedom with a single antiepileptic drug 
(AED), either as initial monotherapy or as a subsequent monother-
apy substitution.2 Theoretically, monotherapy for the treatment of 
epilepsy has a number of advantages over polytherapy including a 
reduced likelihood of adverse events (AEs) and drug- drug interac-
tions, improved compliance and reduced likelihood of pregnancy 
complications.3,4
Lacosamide is approved for the treatment of focal (partial- 
onset) seizures with or without secondary generalization as mono-
therapy	and	adjunctive	therapy	(≥16	years	of	age)	in	the	European	
Union (EU)5	and	 in	the	United	States	 (US)	 (≥17	years	of	age).6 Its 
efficacy as monotherapy in patients with focal seizures has been 
demonstrated in two double- blind randomized trials; a head- 
to- head non- inferiority trial of lacosamide vs the continuous- 
release (CR) formulation of carbamazepine used for EU approval 
(SP993)7; and a historical- controlled, conversion to monotherapy 
trial (SP902) for US approval.8 In the SP993 non- inferiority trial 
in patients with newly diagnosed epilepsy, 73.6% of lacosamide- 
treated and 69.7% of carbamazepine- CR- treated patients (Full 
Analysis Set) completed 6 months on last evaluated dose without 
a seizure.
Randomized controlled trials are considered the gold standard 
in assessing efficacy, but many of these trials can be restrictive in 
design with fixed titration schedules, and doses that are not reflec-
tive of clinical practice.9 As per trial design, patients with certain 
clinical characteristics and comorbidities may be excluded, further 
limiting the applicability of the trial results to a wider population 
of patients. Observational studies may complement findings from 
randomized controlled trials by assessing the effectiveness of an 
intervention in the patients encountered in daily clinical practice. 
In observational studies, physicians are free to individualize titra-
tion and maintenance dosages to optimize efficacy and tolerabil-
ity.9 Additionally, observational studies often have a longer duration 
and more diverse patient populations, including patients with co-
morbidities commonly excluded from randomized controlled trials, 
which means that they may be more likely to detect rare or late- 
onset adverse events (AEs) compared with short- term, randomized 
controlled trials.9
Although the long- term use of lacosamide monotherapy has been 
assessed in an open- label extension to SP902 after conversion to 
monotherapy—where, of the 151 patients who received lacosamide 
monotherapy for the duration of their participation in the study, 107 
had	a	longest	monotherapy	duration	of	≥24	months—there	is	limited	
published clinical practice experience with lacosamide monotherapy. 
A number of smaller open- label and retrospective studies in Europe 
have included patients receiving lacosamide as monotherapy,10-14 
usually after conversion to monotherapy. In a prospective study, 
58 patients converted to lacosamide monotherapy and the major-
ity (63.8%) remained on lacosamide monotherapy after 1 year; 55% 
were seizure free for the treatment period. Giráldez et al11 included 
48 patients who converted to lacosamide monotherapy and 18 AED- 
naïve patients. One- year retention rates were not statistically differ-
ent between groups. In a retrospective study including 199 patients 
treated with adjunctive lacosamide after 1- 2 prior AEDs, 22 patients 
withdrew concomitant AEDs and remained on lacosamide mono-
therapy	for	≥6	months.12
Here we report results from a retrospective chart review of pa-
tients treated with lacosamide monotherapy at specialized epilepsy 
centres in Italy, Spain, and the Netherlands. Patients could be ei-
ther initiated on lacosamide monotherapy (“first- line monotherapy” 




This chart review had a retrospective observation period of 
12 months (±3 months) with a historical baseline of 6 months prior 
to Day 1 (day of first administration of lacosamide monotherapy). 
Observation points (OP) were the first day of lacosamide monother-
apy (OP1), and 6 (±3) and 12 (±3) months after initiating treatment 
(OP2 and OP3). The last documented OP had to take place prior to 
initiation of the chart review; therefore, data collection did not have 
any influence on treatment decisions. The choice of treatment was 
made independently by the physician, according to standard clinical 
practice.
2.2 | Patients
Participating sites reviewed patient charts to identify individuals 
aged	≥16	years	with	focal	seizures	(with	or	without	evolution	to	bi-
lateral tonic- clonic seizures; using the latest ILAE seizure classifica-
tion15) who initiated lacosamide monotherapy (first- line, second- line 
or later) at least 12 months prior to the site initiation and who had 
at least 6 months’ retrospective follow- up documentation after the 
start of lacosamide monotherapy. Two separate groups of patients 
were assessed in this analysis. First- line monotherapy patients were 
required to have experienced at least one seizure during the last 
6 months prior OP1 and to have received no more than 2 weeks’ 
prior AED treatment. Conversion to monotherapy patients (includ-
ing second- line or later lacosamide monotherapy) were required to 
have received other AEDs for longer than 2 weeks before starting 
lacosamide monotherapy. A minimum seizure frequency was not 
required for conversion to monotherapy patients, but seizure fre-
quency during 6 months before the start of lacosamide monother-
apy was recorded.
Cases were excluded if the patient had received lacosamide 
for non- epilepsy indications, had a history of alcoholism or drug 
abuse, or had inaccurate or unreliable clinical records according to 
the treating physician (including patients who had not attended the 
clinic regularly or had not taken medication).
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2.3 | Outcome measures
The primary outcome was retention on lacosamide monother-
apy after at least 12 months of treatment. Secondary outcomes 
included the proportion of patients who were seizure free at 
~6 months (OP2) and at ~12 months (OP3), number of emergency 
room (ER) visits and number and duration of hospitalizations. 
Safety and tolerability variables were the reported frequency of 
adverse drug reactions (ADRs), discontinuation of lacosamide due 
to ADRs, and serious ADRs. An ADR was defined as any untoward 
medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product that was temporally asso-
ciated with the use of that pharmaceutical product and that was 
assessed by the reporter and/or the sponsor as “related” to the 
administration of the pharmaceutical product. A serious ADR was 
defined as an ADR that met one or more of the following criteria: 
death, life- threatening, significant or persistent disability/incapac-
ity, congenital anomaly/birth defect (including that occurring in a 
foetus), important medical event, initial inpatient hospitalization 
or prolongation of hospitalization.
2.4 | Analysis
All analyses were exploratory in nature and missing values were 
not imputed. Safety variables were analysed using the Safety Set 
(all  patients in the database who had been treated with at least one 
dose of lacosamide). Effectiveness and efficacy variables were ana-
lysed using the Full Analysis Set (FAS; all patients in the Safety Set 
[SS]	who	had	post-	baseline	data).	Additional	predefined	subanalyses	
were performed for patients who received lacosamide as first- line 
monotherapy vs those converting from another AED monotherapy, 
for	 those	who	were	 aged	<65	years	 vs	 those	 aged	≥65	years,	 and	
for those patients converting to lacosamide monotherapy who had 
received	≤3	vs	>3	lifetime	AEDs	before	initiating	lacosamide	mono-
therapy. All seizure freedom rates were calculated on the FAS popu-
lation implying that all- cause discontinuations are considered as not 
seizure free.
2.4.1 | Sample size
Assuming a conservative retention rate of 50% (based on the reten-
tion rates observed in a German retrospective study of adjunctive la-
cosamide (data on file) and an Italian prospective study of conversion 
to lacosamide monotherapy,10 63% and 63.8%, respectively) and a 
sample size of 400 patients, two- sided 95% confidence interval (CI) 
covered the estimated retention rate with a precision of <5%.
3  | RESULTS
A total of 439 patients were included in the chart review and were 
evaluable for both effectiveness (FAS) and safety (SS) analyses; 98 
(22.3%) patients had initiated lacosamide as first- line monotherapy; 
341 (77.7%) had converted to lacosamide monotherapy from their 
previous AED treatment (Figure 1). The most commonly docu-
mented reasons for conversion to lacosamide monotherapy were 
lack of  effectiveness of a prior monotherapy (151/439, 34.4%), intol-
erance of previous AED combination therapy (104/439, 23.7%), and 
successful combination therapy with lacosamide (71/439, 16.2%).
Discontinuation of lacosamide monotherapy was documented 
for 18.4% of the patients receiving lacosamide as first- line mono-
therapy. In the conversion to monotherapy patients, 9.4% of the pa-
tients discontinued lacosamide therapy. Lack of effectiveness was 
the most commonly recorded reason for discontinuation for both 
assessment patient groups.
Baseline demographics were generally comparable between 
patients who received lacosamide as first- line therapy and those 
who converted to lacosamide monotherapy (Table 1). Patients 
who received lacosamide as first- line monotherapy had a higher 
incidence of focal evolving to bilateral tonic- clonic seizures 
(54.1% vs 35.5%) compared with patients who converted to 
monotherapy.
The median lacosamide dose in first- line monotherapy and con-
version to monotherapy patients remained stable from baseline to 
each	time	point	(200	mg/d	[min,	max:	50,	400]	and	300	mg/d	[min,	
max: 50, 600], respectively).
3.1 | Retention rate
The retention rates in first- line monotherapy and conversion to mon-
otherapy patients after at least 12 months’ treatment were 60.2% 
(95% CI according to method of Clopper and Pearson16: 49.8%, 
70.0%) and 62.5% (95% CI: 57.1%, 67.6%), respectively; Table 2. In 
sensitivity analyses of the primary variable, estimates of the reten-
tion rate after 12 months using Kaplan- Meier methodology17 were 
81.2% in first- line patients and 91.4% in conversion to lacosamide 
monotherapy patients (Figure 2).
In first- line monotherapy patients, the retention rate for pa-
tients	 aged	≥65	years	 and	 those	 aged	<65	years	was	60.0%	 (95%	
CI: 38.7%, 78.9%) and 60.3% (95% CI: 48.1%, 71.5%), respec-
tively. Retention rates were higher in conversion to monotherapy 
patients	aged	≥65	years	 (68.9%,	95%	CI:	59.1%,	77.7%)	compared	
with younger patients (59.7%, 95% CI: 53.1%, 66.0%). The retention 
rates in conversion to monotherapy patients stratified by number of 




At OP2, 66.3% of first- line monotherapy patients and 63.0% of 
conversion to monotherapy patients were seizure free. At OP3, 
seizure freedom rates were 60.2% and 52.5% for first- line and 
conversion to monotherapy patients, respectively (Figure 3). In 
conversion to monotherapy patients, the seizure freedom rates 
at	OP2	in	patients	who	had	previously	received	≤3	lifetime	AEDs	
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vs	 >3	 lifetime	 AEDs	 were	 65.7%	 vs	 43.9%	 (OR	 2.47;	 95%	 CI	
1.273, 4.781). By OP3, seizure freedom rates in these patients 
had reduced to 55.3% and 31.7%, respectively (OR 2.73; 95% CI 
1.340, 5.554). Seizure freedom rates for first- line monotherapy 
patients	 aged	≥65	years	were	72.0%	at	OP2	and	68.0%	at	OP3.	
Corresponding values in first- line monotherapy patients aged 
<65 years were 64.4% and 57.5%. In conversion to monotherapy 
patients	aged	≥65	years,	seizure	freedom	rates	were	68.0%	at	OP2	
and 56.3% at OP3. Seizure freedom rates at OP2 and OP3 in con-
version to monotherapy patients aged <65 years were 60.9% and 
50.8%, respectively.
3.3 | Emergency room visits and hospitalizations
A total of seven patients (1.6%) visited an ER during the historical 
baseline period, all due to epilepsy. During the observation period, 
11 patients (2.5%) had a documented ER visit while receiving lacosa-
mide monotherapy. Of these, nine patients had one ER visit, one had 
two visits, and one had nine visits. Epilepsy was the documented rea-
son for ER visits for four patients (0.9%). Duration of hospitalization 
was usually short both during the historical baseline period and dur-
ing	the	study	duration	 (median:	1	day).	 In	patients	aged	≥65	years,	
four patients visited the ER, all for reasons other than epilepsy. 
Three patients had one visit and one had two visits. Six patients aged 
<65 years had one ER visit and one patient had more than four ER 
visits. Four patients visited the ER due to epilepsy and four for rea-
sons other than epilepsy, ADRs or elective procedures.
3.4 | Safety and tolerability
ADRs were documented for 52 patients (11.8%) (Table 3), most com-
monly	(≥1%	of	patients)	dizziness	(5.0%),	headache	(2.1%),	and	som-
nolence (1.6%). No serious or severe ADRs were documented, and 
no patients died during the observation period. ADRs of mild inten-
sity were reported by 45 patients (10.3%) with seven (1.6%) patients 
reporting moderate ADRs. Six patients (1.4%) discontinued lacosa-
mide monotherapy due to eight ADRs: dizziness (n = 2), asthenia, 
epigastric discomfort, gait disturbance, irritability, somnolence, and 
vomiting (each n = 1). All but one ADR resolved during the obser-
vation period following treatment discontinuation. One additional 
FIGURE 1 Patient disposition during the retrospective observation period. ADR, adverse drug reaction; OP, observational point. aFull Analysis 
Set	includes	seven	patients	with	a	daily	lacosamide	dose	>400	mg/d.	bSeven patients discontinued lacosamide monotherapy due to ADRs. Six 
patients stopped lacosamide completely and one patient remained on lacosamide adjunctive therapy. cIncludes lost to follow- up (n = 11, 2.5%), 
non- compliance (n = 3, 0.7%), withdrawal (n = 1, 0.2%) and one patient who did not have any seizures. dOP3: 12 months ± 3 months
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patient had a lacosamide dose reduction from 350 mg/d due to 
intermittent mild headache, and concomitant AED medication was 
administered. The patient recovered and remained on lacosamide as 
adjunctive therapy.
Of those patients who received lacosamide as first- line monother-
apy, 11 (11.2%) had a documented ADR compared with 41 (12.0%) pa-
tients who had converted to lacosamide monotherapy. Three patients 
in each subset (3.1% and 0.9%, respectively) discontinued lacosamide 











Age, mean (SD), years 48.8 (19.0) 51.1 (18.8)
<65 y, n (%) 73 (74.5) 238 (69.8)
≥65	y,	n	(%) 25 (25.5) 103 (30.2)
Gender
Male 47 (48.0) 163 (47.8)
Female 51 (52.0) 178 (52.2)
Time since diagnosis, median (min, max), years 0.10 (0.0, 32.7) 4.80 (0.0, 70.3)
Seizure frequency per 28 d, median (min, max) 0.5 (0, 137) 0.6 (0, 77)
Focal seizures (I, partial- onset), n (%)
Aware (IA, simple partial) 27 (27.6) 131 (38.4)
Impaired awareness (IB, complex partial) 56 (57.1) 184 (54.0)
Evolving to bilateral tonic- clonic seizure (IC, partial 
evolving to secondary generalized)
53 (54.1) 121 (35.5)
Generalized seizures (II),a n (%) 0 6 (1.8)
History of seizure clusters and/or status epilepticus 3 (3.1) 17 (5.0)
Aetiology not known 56 (57.1) 168 (49.3)
Idiopathic 6 (6.1) 24 (7.0)
Cryptogenic 50 (51.0) 144 (42.2)
Aetiology knownb 42 (42.9) 173 (50.7)
Cerebrovascular 18 (18.4) 46 (13.5)
Progressive neurodegenerative 0 36 (10.6)
Cranial trauma 6 (6.1) 25 (7.3)
Cerebral neoplasm 5 (5.1) 21 (6.2)
Congenital 6 (6.1) 13 (3.8)
Brain surgery 4 (4.1) 14 (4.1)
Mesial temporal sclerosis 2 (2.0) 16 (4.7)
Cerebral infection 1 (1.0) 8 (2.3)
Perinatal events 1 (1.0) 8 (2.3)
Otherc 3 (3.1) 2 (0.6)
Genetic origin 1 (1.0) 3 (0.9)
Any	prior	AED,	n	(%)	(taken	by	>10%	of	patients	in	the	SS) 21 (21.4) 340 (99.7)
Levetiracetam 6 (6.1) 199 (58.4)
Carbamazepine 2 (2.0) 102 (29.9)
Valproic acid 4 (4.1) 80 (23.5)
Lamotrigine 3 (3.1) 75 (22.0)
Oxcarbazepine 1 (1.0) 46 (13.5)
AED, antiepileptic drug; SD, standard deviation; SS, Safety Set.
aAll patients were also experiencing focal seizures.
bCortical developmental malformations were not predefined and some of these patients may have 
been included in congenital or other categories.
cOther aetiologies were specified in five patients (1.1%) and further described as autoimmune, cor-
tical dysplasia, focal cortical dysplasia, nodular heterotopia and temporal cystic lesion.
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F IGURE  2 Kaplan- Meier estimates for 
time to discontinuation from lacosamide 
monotherapy in subgroups of patients 
who (A) received lacosamide as first- 








Conversion to lacosamide monotherapy
n = 341
≤3 lifetime 
AEDs (n = 300)
>3 lifetime 
AEDs (n = 41)
Patients at OP3, n (%) 85 (86.7) 322 (94.4) 284 (94.7) 38 (92.7)
Patients continuing with 
lacosamide monotherapy, 
n (%)
59 (60.2) 213 (62.5) 186 (62.0) 27 (65.9)
Patients with discontinua-
tion of lacosamide 
monotherapy at OP3, n (%)
26 (26.5) 109 (32.0) 98 (32.7) 11 (26.8)
95% CI for continuation 
(Normal approximation)
50.5; 69.9 57.3; 67.6 56.5; 67.5 51.3; 80.4
95% CI for continuation 
(Clopper- Pearson)
49.8; 70.0 57.1; 67.6 56.2; 67.5 49.4; 79.9
AEDs, antiepileptic drugs; CI, confidence interval; FAS, Full Analysis Set; OP, observational point.
TABLE  2 Retention rate at after 
≥12	mo	of	lacosamide	monotherapy	(OP3)	
(FAS)
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due	to	ADRs.	In	patients	aged	≥65	years,	21	(16.4%)	had	an	ADR	and	
two (1.6%) discontinued lacosamide due to ADRs. Of the patients 
aged <65 years, 31 patients (10.0%) had an ADR and four (1.3%) dis-
continued treatment due to ADRs.
4  | DISCUSSION
This was a retrospective chart review of patients with focal seizures 
who received lacosamide either as first- line monotherapy or after 
converting to lacosamide monotherapy in specialist epilepsy centres.
Retention rates after approximately 12 months of treatment 
(OP3) were comparable in patients who had converted to lacosamide 
monotherapy vs those who received first- line lacosamide monother-
apy. However, using Kaplan- Meier methodology to censor for miss-
ing data, the estimated retention rate among patients converting to 
lacosamide monotherapy was higher than that for first- line mono-
therapy patients. Retention rates were higher in conversion to mono-
therapy	 patients	 aged	 ≥65	years	 compared	with	 younger	 patients.	
There was no difference in retention rates between age groups in 
first- line monotherapy patients. Retention rates in the current trial 
were comparable with those observed in a single- centre, open- label 
study in 58 patients who converted to monotherapy after they had 
experienced 1- year seizure freedom with adjunctive lacosamide.10 
Moreover, these retention rates are also consistent with the 59.3% 
retention rate at 1 year described in a study of 59 adults receiving la-
cosamide in adjunctive use.18 When comparing to Kaplan- Meier es-
timates the 1- year retention rates in our study are higher than those 
described in another long- term follow- up study with lacosamide in 
adjunctive use (74.5% Kaplan- Meier estimates).19 However, this may 
be due to the less severe patient population included into our study.
In general, seizure freedom rates were lower at ~12 months 
(OP3) than at ~6 months (OP2) but were higher in patients who re-
ceived lacosamide as first- line monotherapy compared with those 
who converted to monotherapy (60.2% and 52.5%, respectively, at 
~12	months	 [OP3]	 and	66.3%	and	63.0%	at	 ~6	months	 [OP2]).	As	
may be expected, seizure freedom rates were higher in conversion 
to	monotherapy	patients	who	had	received	≤3	 lifetime	AEDs	prior	
to	 lacosamide	 monotherapy	 vs	 those	 with	 >3	 lifetime	 AEDs	 and	
who are more treatment- resistant (55.3% vs 31.7%, respectively, 
at	~12	months	[OP3]).	Notably,	in	this	study,	seizure	freedom	rates	
were calculated using the full FAS not just patients completing treat-
ment. These results are consistent with those from SP993, where 
73.6% of newly diagnosed epilepsy patients treated with lacosamide 
monotherapy completed 6 months’ and 59.5% completed 12 months’ 
treatment without seizures.7 Smaller studies have also shown com-
parable seizure freedom rates.10,11 A retrospective chart review per-
formed at six Spanish centres showed higher, but not significantly 
different, seizure freedom rates in drug- naïve patients (n = 18) vs 
those with prior AED treatment (n = 48) (72.2% vs 60.4%; P = .375).11 
F IGURE  3 Seizure- free status at OP2 
and OP3 on lacosamide monotherapy in 
subgroups of (A) first- line monotherapy 
and (B) conversion to monotherapy 
patients
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A history of treatment with fewer than three lifetime AEDs was pre-
dictive of seizure freedom (unadjusted OR 6.30, 95% CI 1.85- 21.48, 
P = .003; adjusted OR 6.38, 95% CI 1.85- 21.98, P = .003) in a pro-
spective, 1- year, open- label study in a clinical practice setting.10 In 
the current study, in both first- line and conversion to monotherapy 
patients	a	larger	proportion	of	patients	aged	≥65	years	were	seizure	
free at OP2 (and OP3) compared with younger patients.
This chart review recorded ER visits and hospitalizations, but as 
the amount of missing values cannot be sufficiently derived from 
the received retrospective study data, reasonable conclusions are 
not possible for these variables. It was noted, however, that few 
patients required hospitalization or visited an ER during the obser-
vation period.
Lacosamide was generally well tolerated with a low frequency of 
ADRs (11.8% in the overall population). The recorded ADRs were con-
sistent with those observed in clinical trials of lacosamide as mono-
therapy and as adjunctive therapy,7,8,20 and the incidence of ADRs 
was comparable between first- line monotherapy and conversion 
to monotherapy patients. Dizziness was the most commonly docu-
mented ADR in the overall and elderly population (5.0% and 8.6%, 
respectively); however, the incidence of dizziness was lower than that 
observed in a Phase III trial in newly diagnosed epilepsy (12%)7 and 
considerably lower than in a conversion to monotherapy trial (24.0%) 
using a fixed titration schedule for lacosamide before the withdrawal 
of the baseline drugs.8 While the low documented incidence of dizzi-
ness may indicate a level of underreporting of less severe AEs in ret-
rospective studies, it may also be possible that the incidence of this 
ADR is lower in clinical practice due to individualized titration (usu-
ally slower than in clinical trials) and dosing. Indeed, cross- titration 
and flexible titration have previously been suggested as feasible and 
practical approaches for dosing lacosamide while minimizing pharma-
codynamic interactions with a sodium channel blocking AED.21 The 
incidence	of	ADRs	in	patients	aged	≥65	years	 (16.4%)	tended	to	be	
higher than that observed in those aged <65 years (10.0%).
Discontinuation of lacosamide due to ADRs was uncommon and 
occurred more frequently in first- line patients compared with conver-
sion to monotherapy patients (3.1% vs 0.9%, respectively). There was 
no difference in discontinuations due to ADRs between patients aged 
≥65	years	and	those	aged	<65	years	(1.6%	vs	1.3%,	respectively).	No	
serious or severe ADRs (including adverse cardiac affects) or deaths 
were documented, and no new safety signals were identified.
The lacosamide doses received by first- line monotherapy pa-
tients	 included	 in	 this	 study	 (median	200	mg	 [min,	max:	 50,	 400])	
were lower than those used as adjunctive therapy in a similar retro-
spective study in Spain22 and a prospective observational study in 
Germany.23 Lacosamide doses used by conversion to monotherapy 
patients	 (median	300	mg	[min,	max:	50,	600])	were	comparable	to	
those used in these two studies.
Interpretation of the results of this study is limited by the ret-
rospective design of the study, potential inclusion bias, and the ex-
ploratory nature of the analyses. There was also the potential for 
underreporting of ADRs and possibly also of hospitalizations, ER 
visits and healthcare provider outpatient consultations. There are 
also likely to be substantial differences between treatment centres 
and countries in treatment and patients. Despite these limitations, 
this study benefitted from patients receiving expert- based diagno-
sis, observation and treatment from tertiary epilepsy centres, and 
also provides valuable information on the safety and effectiveness 
of lacosamide monotherapy in a real- world setting. A prospective 
study in clinical practice would help provide additional information 
on the clinical utility of lacosamide monotherapy including fur-
ther monotherapy studies in special populations complementing 
the existing experience in adjunctive use (eg brain tumour- related 
epilepsy).24
TABLE  3  Incidence of adverse drug reactions (ADRs, SS)
Overall 
(n = 439)
Aged <65 y 
(n = 311)
Aged ≥65 y 
(n = 128)
n (%) n (%) n (%)
Any ADR 52 (11.8) 31 (10.0) 21 (16.4)
Serious ADR 0 0 0
Severe ADR 0 0 0
Discontinuation 
due to ADR
6 (1.4) 4 (1.3) 2 (1.6)
Deaths 0 0 0
Incidence of individual ADRs
Dizziness 22 (5.0) 11 (3.5) 11 (8.6)
Headache 9 (2.1) 7 (2.3) 2 (1.6)
Somnolence 7 (1.6) 3 (1.0) 4 (3.1)
Abdominal 
discomfort
2 (0.5) 2 (0.6) 0
Asthenia 2 (0.5) 0 2 (1.6)
Constipation 2 (0.5) 2 (0.6) 0
Gait disturbance 2 (0.5) 2 (0.6) 0
Irritability 2 (0.5) 2 (0.6) 0
Nausea 2 (0.5) 0 2 (1.6)
Anxiety 1 (0.2) 1 (0.3) 0
Depression 1 (0.2) 1 (0.3) 0
Diplopia 1 (0.2) 1 (0.3) 0
Dysuria 1 (0.2) 0 1 (0.8)
Epigastric 
discomfort
1 (0.2) 1 (0.3) 0
Fatigue 1 (0.2) 1 (0.3) 0
Flatulence 1 (0.2) 1 (0.3) 0
Increased 
appetite
1 (0.2) 1 (0.3) 0
Insomnia 1 (0.2) 1 (0.3) 0
Mood altered 1 (0.2) 0 1 (0.8)
Paraesthesia 1 (0.2) 1 (0.3) 0
Solar dermatitis 1 (0.2) 0 1 (0.8)
Vertigo 1 (0.2) 1 (0.3) 0
Vomiting 1 (0.2) 1 (0.3) 0
ADR, adverse drug reaction; SS, Safety Set.
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5  | CONCLUSIONS
The results of this retrospective, non- interventional chart review indi-
cate that lacosamide monotherapy may be an effective treatment op-
tion for focal seizures in patients receiving their first AED monotherapy 
and for those converting to lacosamide monotherapy from other AEDs.
ACKNOWLEDG EMENTS
The authors thank the patients and their caregivers in addition to the 
clinical project team and the investigators and their teams who con-
tributed to this trial. The authors also acknowledge Suzannah Ryan, 
PhD (UCB Pharma, Dublin, Ireland) for publication coordination and 
Jonathon Gibbs, CMPP (Evidence Scientific Solutions, Horsham, UK) 
for writing support which was funded by UCB Pharma.
CONFLIC T OF INTERE S T
M. De Backer and L. Joeres are employees of UCB Pharma. M. Brunnert 
and P. Dedeken were employees of UCB Pharma at the time of the 
study. V. Villanueva has participated in advisory boards and pharma-
ceutical industry- sponsored symposia for Eisai, UCB Pharma, Merck 
Sharp & Dohme, Bial, Pfizer, GSK, Esteve, Novartis, Shire, Medtronic 
and Cyberonics. M. Toledo has received grants from UCB Pharma, 
Bial, Eisai and honoraria from UCB Pharma, Bial, Eisai, GSK, Shire and 
Esteve. G.J. De Haan has participated in advisory boards for Eisai, UCB 
Pharma and GSK, and was moderator in workshops sponsored by UCB 
Pharma and GSK. E. Cumbo has participated in advisory boards and 
pharmaceutical industry- sponsored symposia for Pfizer, UCB Pharma, 
Novartis Pharma and Lundbeck. J. Serratosa has received honoraria 
from UCB Pharma, Esteve, Eisai, Bial and Cyberonics for participating 
in advisory boards and pharmaceutical industry- sponsored symposia.
ORCID
M. Toledo  http://orcid.org/0000-0003-3208-2496 
R E FE R E N C E S
 1. Panayiotopoulos CP. The Epilepsies: Seizures, Syndromes and 
Management. Oxfordshire, UK: Bladon Medical Publishing; 2005.
 2. Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or 
add- on? Seizure. 2000;9:464-468.
 3. St Louis EK, Rosenfeld WE, Bramley T. Antiepileptic drug mono-
therapy: the initial approach in epilepsy management. Curr 
Neuropharmacol. 2009;7:77-82.
 4. Tomson T, Battino D, Bonizzoni E, et al. Antiepileptic drugs and in-
trauterine death: a prospective observational study from EURAP. 
Neurology. 2015;85:580-588.
 5. European Medicines Agency. Vimpat (Lacosamide). EMA Summary 
of Product Characteristics. Brussels, BE: UCB Pharma SA; 2017.
 6. UCB Pharma Inc. Vimpat (Lacosamide) US Prescribing Information. 
Smyrna, GA: UCB Pharma Inc; 2017.
 7. Baulac MJ, Rosenow F, Toledo M, et al. Efficacy and tolerability of 
lacosamide monotherapy versus controlled- release carbamazepine 
in patients with newly- diagnosed epilepsy: a phase 3 randomised 
double- blind non- inferiority trial. Lancet Neurol. 2016;16:43-54.
 8. Wechsler RT, Li G, French J, et al. Conversion to lacosamide 
monotherapy in the treatment of focal epilepsy: results from a 
historical- controlled, multicenter, double- blind study. Epilepsia. 
2014;55:1088-1098.
 9. Concato J. Observational versus experimental studies: what’s the 
evidence for a hierarchy? NeuroRx. 2004;1:341-347.
 10. Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M. 
Lacosamide monotherapy for partial onset seizures. Seizure. 
2015;27:71-74.
 11. Giráldez BG, Toledano R, Garcia-Morales I, et al. Long- term efficacy 
and safety of lacosamide monotherapy in the treatment of partial- 
onset seizures: a multicenter evaluation. Seizure. 2015;29:119-122.
 12. Villanueva V, Garces M, Lopez-Gomariz E, et al. Early add- on lacos-
amide in a real- life setting: results of the REALLY study. Clin Drug 
Invest. 2015;35:121-131.
 13. Borzi G, di Gennaro G, Schmitt FC, et al. Lacosamide in patients 
with temporal lobe epilepsy: an observational multicentric open- 
label study. Epilepsy Behav. 2016;58:111-114.
 14. Stephen LJ, Kelly K, Parker P, Brodie MJ. Adjunctive la-
cosamide–5 years’ clinical experience. Epilepsy Res. 
2014;108:1385-1391.
 15. Fisher RS, Cross JH, French JA, et al. Operational classification of 
seizure types by the International League Against Epilepsy: position 
paper of the ILAE Commission for Classification and Terminology. 
Epilepsia. 2017;58:522-530.
 16. Clopper CJ, Pearson ES. The use of confidence or fiducial limits il-
lustrated in the case of the binomial. Biometrika. 1934;26:404-413.
 17. Kaplan EL, Meier P. Nonparametric estimation from incomplete ob-
servations. J Am Stat Assoc. 1958;53:457-481.
 18. Verrotti A, Loiacono G, Pizzolorusso A, et al. Lacosamide in pedi-
atric and adult patients: comparison of efficacy and safety. Seizure. 
2013;22:210-216.
 19. Rosenow F, Kelemen A, Ben-Menachem E, McShea C, Isojarvi J, 
Doty P. Long- term adjunctive lacosamide treatment in patients with 
partial- onset seizures. Acta Neurol Scand. 2016;133:136-144.
 20. Biton V, Gil-Nagel A, Isojarvi J, Doty P, Hebert D, Fountain NB. 
Safety and tolerability of lacosamide as adjunctive therapy for 
adults with partial- onset seizures: analysis of data pooled from 
three randomized, double- blind, placebo- controlled clinical trials. 
Epilepsy Behav. 2015;52:119-127.
 21. Baulac M, Byrnes W, Williams P, et al. Lacosamide and sodium 
channel- blocking antiepileptic drug cross- titration against levetirac-
etam background therapy. Acta Neurol Scand. 2017;135:434-441.
 22. Villanueva V, Lopez FJ, Serratosa JM, et al. Control of seizures in 
different stages of partial epilepsy: LACO- EXP, a Spanish retro-
spective study of lacosamide. Epilepsy Behav. 2013;29:349-356.
 23. Runge U, Arnold S, Brandt C, et al. A noninterventional study eval-
uating the effectiveness and safety of lacosamide added to mono-
therapy in patients with epilepsy with partial- onset seizures in daily 
clinical practice: The VITOBA study. Epilepsia. 2015;56:1921-1930.
 24. Toledo M, Molins A, Quintana M, et al. Outcome of cancer- related 
seizures in patients treated with lacosamide. Acta Neurol Scand. 
2018;137:67-75.
How to cite this article: Villanueva V, Giráldez BG, Toledo M, 
et al. Lacosamide monotherapy in clinical practice: A 
retrospective chart review. Acta Neurol Scand. 2018;00:1–9. 
https://doi.org/10.1111/ane.12920
